| Literature DB >> 33553666 |
Mohamed Shalaby1, Tarek S El Baradie1, Mohamed Salama1, Hebat A M Shaaban2, Rasha M Allam3, Ehab O A Hafiz4, Mohamed Aly Abdelhamed1, Amr Attia1.
Abstract
BACKGROUND AND AIM: Colorectal cancer (CRC) accounts for over 8% of all deaths each year, with 1.2 million new cases diagnosed annually worldwide. It represents the seventh most common cancer in Egypt. Early detection of peritoneal metastasis is a major challenge in such cases. It helps with the decision of the immediate application of intraperitoneal chemotherapy after resection. Meta-analysis studies reported contrast evidence for a possible prognostic role of intraperitoneal free cancer cells (IPCCs) in peritoneal recurrence and survival after curative resection. In this work, we aim to evaluate the prevalence and impact of detecting free malignant cells in peritoneal fluid on survival and local recurrence and to estimate the incidence of peritoneal carcinomatosis (PC) during follow up.Entities:
Keywords: colorectal cancer; cytology; peritoneal; recurrence
Year: 2020 PMID: 33553666 PMCID: PMC7857300 DOI: 10.1002/jgh3.12482
Source DB: PubMed Journal: JGH Open ISSN: 2397-9070
Correlation between the patient characteristics, tumor characteristics, serology tests, and sample volume with the cytology results (n = 96)
| Variable | Cytology (−) ( | Cytology (+) ( |
|
|---|---|---|---|
| Patient characteristics | |||
| Age | 0.538 | ||
| ≤55.5 | 38 (86.4) | 6 (13.6) | |
| >55.5 | 47 (90.4) | 5 (9.6) | |
| Gender | |||
| Male | 41 (89.1) | 5 (10.9) | 0.862 |
| Female | 44 (88) | 6 (12) | |
| Site of cancer | |||
| Colon | 55 (87.3) | 8 (12.7) | 0.598 |
| Rectum | 30 (90.9) | 3 (9.1) | |
| Performance status | |||
| PS1 | 65 (86.7) | 10 (13.3) | — |
| PS2 | 19 (95) | 1 (5) | |
| PS3 | 1 (100) | 0 (0) | |
| Tumor characteristics | |||
| Tumor stage ( | |||
| T2 | 12 (100) | 0 (0) | 0.122 |
| T3 | 64 (87.7) | 9 (12.3) | |
| T4 | 6 (100) | 0 (0) | |
| Lymph node ( | |||
| N0 | 45 (95.7) | 2 (4.3) | 0.128 |
| N1 | 25 (83.3) | 5 (16.7) | |
| N2 | 12 (85.7) | 2 (14.3) | |
| Stage ( | |||
| I and II | 45 (95.7) | 2 (4.3) | 0.08 |
| III | 37 (84.1) | 7 (15.9) | |
| Histological type | |||
| Mucinous adenocarcinoma | 13 (15.3) | 6 (54.5) | <0.001 |
| Signet ring | 5 (5.9) | 3 (27.3) | |
| Well‐differentiated | 67 (78.8) | 2 (18.2) | |
| Serological tests and sample volume | |||
| CEA | |||
| ≤3 ( | 32 (94.1) | 2 (5.9) | 0.22 |
| >3 ( | 22 (81.5) | 5 (18.5) | |
| CA 19–9 | |||
| ≤11 ( | 29 (93.5) | 2 (6.5) | 0.25 |
| >11( | 25 (83.3) | 5 (16.7) | |
| Sample volume | |||
| ≤(120 mL) | 48 (84.2) | 9 (15.8) | 0.107 |
| >(120 mL) | 37 (94.9) | 2 (5.1) | |
Correlation between tumor lymphovascular invasion, tumor perforation, patient management, recurrence and metastases, and post‐operative status with the cytology results (n = 96)
| Character | Cytology (−) ( | Cytology (+) ( |
|
|---|---|---|---|
| Tumor‐related factors | |||
| Lymphovascular invasion ( | 5 (5.9) | 3 (27.3) | 0.016 |
| Perforated Tumor ( | 6 (7.1) | 1 (9.1) | 0.807 |
| Management | |||
| Resection ( | |||
| Curative | 82 (96.5) | 9 (81.8) | 0.099 |
| Irresectable | 3 (3.5) | 2 (18.2) | |
| Composite resection | 7 (8.2) | 2 (18.2) | 0.287 |
| Adjuvant CTH ( | |||
| Yes | 48 (60) | 9 (81.8) | 0.161 |
| No | 32 (40) | 2 (18.2) | |
| Neoadjuvant CTH | |||
| Yes | 24 (28.2) | 4 (36.4) | 0.577 |
| No | 61 (71.8) | 7 (63.6) | |
| Recurrence and spread | |||
| Peritoneal recurrence ( | 5 (6.3) | 1 (9.1) | 0.731 |
| Local recurrence ( | 3 (3.8) | 1 (9.1) | — |
| Distant metastasis ( | 7 (8.9) | 5 (45.5) | <0.001 |
| Postoperative status | |||
| Medical comorbidity ( | 24 (28.2) | 2 (18.2) | 0.480 |
| Postoperative complications ( | 15 (17.6) | 0 (0) | 0.129 |
Figure 1(a) Graph showing the relation between tumor histologic type and positive peritoneal cytology (P‐value <0.001). (b) Giemsa‐stained smear (diff‐quick stain) and SurePath LBC smear (Papanicolaou stain) featuring metastatic adenocarcinoma of primary colorectal origin [original magnification x400]. Graph showing high incidence of positive peritoneal cytology in cases with distant metastases (P‐value <0.001) (c) and patients with peritoneal and local recurrence (d).
Figure 2(a) Graph showing the relation between patients' age and OS (P‐value 0.009). (b) Graphs showing relation between tumor stage (pT) and OS (P‐value 0.015) and DFS (P‐value 0.001). Lower OS was encountered at a higher rate with perforated tumors (P‐value 0.042) as shown in the graph (c). Composite resection was associated with a considerable deleterious effect on survival outcome and DFS (P‐value 0.054 and 0.003, respectively) (d).
Figure 3Medical comorbidity is an ominous sign for both OS and DFS graphs (a). The presence of postoperative complications is an independent poor prognostic factor regarding OS and DFS graphs (b), while adjuvant CTH has increased survival significantly (P‐value 0.015) graphs (c). Graphs (d) show irrelevance between cytology results and OS or DFS. Serum CEA showed an adverse prognostic value in DFS prediction either alone or combined with cytology results (P‐values of 0.019 and 0.039, respectively) (e).